Sector |
|
Compare with Sector peers |
Industry |
|
Compare with Industry peers |
Website | http://www.camlinfs.com | |
Market Cap | 1,860.12 Cr. | |
Enterprise Value(EV) | 2,340.57 Cr. | 2022-03 |
Financial Indicators | ||
---|---|---|
Earnings per share (EPS) | 3.86 | Trailing Twelve Months Ending 2022-03 |
Price-Earning Ratio (PE) | 30.66 | Trailing Twelve Months Ending 2022-03 |
Industry PE | 29.51 | Trailing Twelve Months Ending 2022-03 |
Book Value / Share | 47.63 | Trailing Twelve Months Ending 2022-03 |
Price to Book Value | 2.49 | Calculated using Price: 118.45 |
Dividend Yield | 0.00 | Period Ending 2021-03 |
No. of Shares Subscribed | 15.70 Cr. | 157,037,996 Shares |
FaceValue | 1 | |
Company Profile | ||
Camlin, the corporate group, was established in 1931 and is a pioneer in art and stationery material in Camlin Fine Chemicals is the world's second largest manufacturer and marketer of food grade antioxidants TBHQ and BHA. Its mission is to be the largest food antioxidant and ingredient manufacturer worldwide. Their facilities are HACCP and ISO 9001 : 2000 certified. a) Food Ingredients – Antox TBHQ (HACCP Certified) FCC V / FAO / WHO (Tertiary Butyl Hydroquinone) Antox BHA (HACCP Certified) FCC V / FAO / WHO / EEC ( Butyl Hydroxy Anisole) b) Sweetener - Sucralose FCC V c) Active Pharmaceutical Ingredients -
d) Super Absorbent Polymer Subsidiary Details:
On 6th June 2008 - The company entered into a joint venture, on 51:49 basis, with US based Viachem LLC, to set up a joint venture company under the name Dulcette Technologies for marketing Sucralose, Aspartame, and Acesulfame-K, and their belnds in On 7th July 2008 - The Board of Directors of the company at its meeting held on 29th July 2008, approved the proposal for setting up a joint venture company with Pagoda Advisors and their associates. As per the deal, Camlin Fine Chemicals will get 51% of the equity of the proposed new company and the rest 49% will be owned by Pagoda Advisors and their associates.The proposed new company will focus on the retail of luxury/premium brands in On 25th February 2008: Camlin Fine Chemicals acquired 60% equity stake in Sangam Laboratories, a Small Scale Unit manufacturing Nutraceuticals and Drug Intermediates at Tarapur. On 12th February 2008 - The company inked a joint venture deal with US based Advanced Aerospace Technologies to manufacture and market speciality fine chemicals primarily to cater to European and U.S markets. |
1 Day |
|
-2.83% |
1 Week |
|
+6.76% |
1 Month |
|
-9.48% |
3 Month |
|
-7.68% |
6 Month |
|
-23.53% |
1 Year |
|
-35.90% |
2 Year |
|
+227.21% |
5 Year |
|
+53.53% |
10 Year |
|
+931.79% |
9 years | 2013-03 | 2014-03 | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | |
Return on Equity (%) | 25.61 | 36.29 | 48.31 | 23.04 | -2.30 | -8.63 | 0.88 | 7.94 | 14.61 | |
Return on Capital Employed (%) | 23.65 | 27.41 | 28.50 | 22.86 | 5.45 | 0.14 | 7.32 | 12.02 | 15.25 | |
Return on Assets (%) | 4.62 | 7.83 | 14.15 | 8.13 | -0.80 | -2.97 | 0.30 | 2.66 | 4.95 |
Particulars | 10 years | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03* Rs. Cr. |
Shh. Funds | 65 | 93 | 135 | 176 | 213 | 371 | 371 | 403 | 643 | 748 | |
Non Curr. Liab. | 41 | 25 | 17 | 12 | 33 | 73 | 155 | 185 | 258 | 403 | |
Curr. Liab. | 263 | 246 | 262 | 280 | 386 | 471 | 460 | 548 | 478 | 595 | |
Minority Int. | 18 | 62 | 59 | 57 | 70 | 17 | |||||
Equity & Liab. | 369 | 365 | 413 | 468 | 648 | 977 | 1,046 | 1,193 | 1,449 | 1,764 | |
Non Curr. Assets | 86 | 108 | 115 | 168 | 229 | 311 | 373 | 518 | 654 | 870 | |
Curr. Assets | 283 | 257 | 299 | 300 | 419 | 666 | 672 | 675 | 795 | 894 | |
Misc. Exp. not W/O | |||||||||||
Total Assets | 369 | 365 | 413 | 468 | 648 | 977 | 1,046 | 1,193 | 1,449 | 1,764 |
Particulars | 10 years | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. TTM |
Net Sales | 374 | 509 | 558 | 489 | 534 | 721 | 892 | 1,049 | 1,187 | 1,412 | |
Other Income | 11 | 12 | 8 | 4 | 16 | 13 | 14 | 3 | 11 | 38 | |
Total Income | 385 | 521 | 567 | 494 | 550 | 734 | 906 | 1,053 | 1,198 | 1,450 | |
Total Expenditure | -328 | -449 | -474 | -398 | -503 | -706 | -819 | -914 | -1,000 | -1,269 | |
PBIDT | 57 | 71 | 93 | 96 | 46 | 28 | 87 | 139 | 198 | 181 | |
Interest | -20 | -25 | -24 | -24 | -31 | -32 | -41 | -48 | -48 | -31 | |
Depreciation | -14 | -12 | -16 | -17 | -22 | -27 | -29 | -33 | -44 | -56 | |
Taxation | -8 | -6 | 2 | -14 | 2 | 7 | -14 | -28 | -40 | -34 | |
Exceptional Items | 0 | -5 | |||||||||
PAT | 15 | 29 | 55 | 36 | -4 | -24 | 3 | 30 | 65 | 61 | |
Minority Interest | -7 | -6 | -2 | 0 | -14 | 0 | |||||
Share Associate | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||
Other Related Items | |||||||||||
Consolidated Net Profit | 15 | 29 | 55 | 36 | -11 | -30 | 1 | 30 | 51 | 61 | |
Adjusted EPS | 2 | 3 | 6 | 4 | -1 | -2 | 0 | 3 | 4 | 5 |
Particulars | 10 years | 2012-03 Rs. Cr. | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. |
Cash Fr. Operatn. | -32 | 56 | 27 | 46 | 72 | -9 | -15 | -9 | 86 | 117 | |
Cash Fr. Inv. | -9 | -19 | -32 | -26 | -66 | -83 | -149 | -2 | -90 | -133 | |
Cash Fr. Finan. | 38 | -21 | -6 | -15 | -7 | 91 | 182 | 26 | 3 | 39 | |
Net Change | -3 | 16 | -12 | 4 | -1 | -1 | 18 | 15 | -1 | 23 | |
Cash & Cash Eqvt | 10 | 26 | 5 | 9 | 8 | 21 | 38 | 53 | 52 | 76 |
Tue, 24 May 2022
Compliances-Reg.24(A)-Annual Secretarial Compliance Annual Secretarial Compliance Report |
Mon, 23 May 2022
Announcement under Regulation 30 (LODR)-Earnings Call Transcript Earnings Call Transcript |
Fri, 20 May 2022
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Details of Loss of Certificate |
Wed, 25 May 2022 |
|
|
|
|
|